Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
NCT06761911Phase 4Not yet recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 4, open-label trial of brentuximab vedotin in Classical Hodgkin Lymphoma (cHL) (2 arms). Primary endpoints: Preliminary Overall Response Rate and Progression-free survival up to 3 years. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
Classical Hodgkin Lymphoma (cHL)
Beyond the preview
Go deeper on NCT06761911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06761911.